继发于Castleman病的闭塞性细支气管炎治疗研究进展

Research progress in the treatment of bronchiolitis obliterans secondary to Castleman disease

目的闭塞性细支气管炎(BO)是由多种因素引起的细支气管炎性损伤所致的慢性气流阻塞性肺病,Castleman病(CD)是一种少见的异质性慢性淋巴组织增殖性疾病。继发于CD的BO病例临床上罕见,发病机制与CD相关的免疫紊乱有关,病情常进展至呼吸衰竭,病死率高;目前无统一有效的治疗方案,为控制BO病情进展,临床主要采用糖皮质激素、免疫抑制剂、免疫调节药物及靶向药物等手段治疗。文章就CD合并BO的治疗作一综述,探索对该病有效的治疗方法。

Bronchiolitis obliterans(BO)is a chronic airflow obstructive pulmonary disease caused by bronchiolitis caused by multiple factors.Castleman disease(CD)is a rare heterogeneous chronic lymphoid tissue proliferative disease.Cases of BO secondary to CD are clinically rare,and the pathogenesis is related to CD-related immune disorders,the disease often progresses to respiratory failure,and the mortality rate is high.At present,there is no uniform and effective treatment plan.In order to control the progression of BO disease,clinical treatments are mainly using glucocorticoids,immunosuppressants,immunomodulatory drugs and targeted drugs.This article reviews the treatment of CD combined with BO and explores effective treatment methods for the disease.